noretreat, my thoughts are that based on the Beacon report we should be heading toward the $8 now (esp since it is based on a 2% market penetration and does not take into account any other indication). The gap to me is Don's inability at this time to sell the value in my judgement. Obviously it is very complex with the uncertainty on the science side but in my opinion the science side is far cleaner than the business side.

Don is setting a precident in the declining value of the financing deals. Given the consistent and incredible developments on the science side since Aug 2013 (and long before re SUSTAIN, ASSURE, etc - let's note forget that these trials produced highly statistically significant findings in increasing functional HDL) the value of deals should be significantly above the first Hepa agreement for China. In fact it is declining.

On the share structure side Hepalink holds 42.9% (75 million shares) without their warrants exercised. According to the latest update 30.5% of shares (53 million shares) are widely held but my guess, and it is completely a guess, is that large chunks of these shares are held by longs like me, the influx of apparent institutional investors post the debt pay out and the Beacon report, and blocks held by BPs. I think there could be some profit taking action if the share price moved up above the $4 level or earlier for the traders within the 30.5%.

I do not know much about the stock market at all but I think this stock is thinnly traded ( lol ).

In my mind there are 2 issues that could unleash some value in this stock.

One is passing the futility analysis. Marcel Wijma puts the LOA (likelihood of FDA approval) based on current knowledge at 55% after a comparison with a large data base across many trials (Biomedtracker database). Passing the FA should increase the LOA probability.

Second, the quality, depth and value of the next financing. Don claims he is working on many LOIs (I don't know where he finds the time to do quality work on so many LOIs but I'll give him the benefit of the doubt).

1. The first hurdle is the $ amount to be provided. Will it be done in dribs and drabs where the company limps along by the quarter or will it be full funding of BoM plus all of the other trials that are now lagging behind? Will the funding bring better balance to the share structure?
2. The second is at what cost. Clearly, if Don has to give more away at lower prices it is not a signal that he is in a position of negotiating power.
3. The third is the quality of the investor. An investor with an established strong reputation in biotech would be a strong signal that bright scientific and business minds have studied apabetalone and RVX and the potential of it's science, platforms, processes and the 2500 compounds already produced. For example if Eastern's biotech comes back in with renewed interest after his California disaster it could balance the power structure in the shares and it gives a big vote of confidence in both the science and the business. Another consideration would be another regional deal, perhaps in the EU or even to compete with Hepalink's USA FROR would be a strong vote of confidence and a bidding war could really drive up the price of the deal. And there are many options but a repeat of the Medison Israel deal obviously would not cut it (I'm still scratching my head but apparently Don said "you'll see (it's significance)" in regard to this deal).

So, you are right, we'll sit and wait. As frustrated as I am about management I will wait with my shares in hand because I am in the camp of breakthrough science. So now while Don does multiple LOIs he is also raising $10,000,000 in a PP for Zenith pre IPO (LOL!). When he does raise this money who the funder is may yield some very positive signals about the significance of this potentially breakthrough science.

I'm sure the financing will be done but the nature of a deal has me concerned. I'd love to wear egg on my face! Prove me wrong Don. Come up with a blockbuster or at least move the share price to where is should be!

GLTA

Toinv